ArticleThe Journal of clinical endocrinology and metabolism2026
Identifying TMEM127-deficient pheochromocytomas/paragangliomas via RET overexpression by immunohistochemistry.
Article in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
19 authors.
Funding
Abstract
contextPheochromocytomas and paragangliomas (PPGLs) are rare, genetically diverse tumors originating from the adrenal medulla or extra-adrenal paraganglia, respectively. Knowledge of the pathogenic status of genetic variants, especially in the 35-40% of patients with germline changes, impacts management and family surveillance. However, interpreting variants of uncertain significance (VUS) remains challenging, particularly for poorly characterized genes such as TMEM127, and often requires additional testing. We recently reported that TMEM127 loss promotes RET accumulation by reducing its degradation.
objectiveWe evaluated RET expression by immunohistochemistry (IHC) as a potential aid to highlight TMEM127 dysfunction in PPGLs carrying TMEM127 germline variants.
methodsWe performed RET IHC in 104 formalin-fixed and paraffin-embedded (FFPE) sections of clinically and genetically diverse PPGLs and generated histochemical scores (H-S) manually for membrane (MH-S), cytoplasm (CH-S) and their sum (total TH-S), and digitally for CH-S and TH-S.
resultsTumors driven by TMEM127 variants carried the highest RET expression scores (151.8 ± 62), predominantly MH-S, when compared with other PPGL genotypes, including RET pathogenic disruptions (69.9 ± 96.8, adjusted p = 0.03) or tumors of undefined genotype (40.8 ± 69, adjusted p = 0.0001). Digital scoring showed high correlation with manual H-S (0.74 and 0.80 for C-HS and TH-S, respectively). RET membrane immunoreactivity also distinguished PPGLs carrying likely damaging from non-disrupting TMEM127 variants.
conclusionsThese findings point to increased RET membrane expression as a promising biomarker for loss-of-function TMEM127 variants in PPGLs. If validated in independent cohorts, RET IHC could be an effective tool for assessing the functional implications of PPGLs from patients carrying TMEM127 VUS.
Indexed as
Identifiers
42464758What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.